Transformative Portfolio Expansion Presentation
Filed with ASX · · 26 pages · English
A platform technology that can be leveraged to develop multiple new therapies Triples Chimeric’s pipeline adding 5 new cell therapy assets Broadens Chimeric’s reach into 10+ disease areas including blood cancers and solid tumours Extends Chimeric’s clinical development program with 5 new clinical trials by 2023 Ability to further leverage the platform through partnerships or licensing Propels Chim
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- CLTX CAR T data shows regional control of tumour recurrence
- CLTX CAR t presents positive initial phase 1 clinical data
- First milestone on path to CDH17 CAR t clinical trial
- European patent granted for CLTX technology used in CHM 1101
- Partnership with OncoBay Clinical to advance CHM 1101
Later from Chimeric Therapeutics
- Chimeric receives US patent covering CLTX CAR technology
- Sponsored Research Agreement with University of Pennsylvania
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Entitlement Offer to raise approximately $18.1 million
- Successful completion of Institutional Entitlement Offer
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics